onasemnogene abeparvovec sold brand name zolgensma gene therapy used treat spinal muscular atrophy disease causing muscle function loss children involves onetime infusion medication works providing new copy smn gene produces smn common side effects include vomiting elevated liver enzymes severe reactions involve liver issues low platelet sma stems gene mutation causing smn protein deficiency vital motor neuron survival onasemnogene abeparvovec biologic drug utilizing virus capsids containing transgene administered motor neurons boosting smn protein levels developed avexis acquired novartis onasemnogene abeparvovec gained various fda designations approvals globally controversies included data manipulation concerns delayed reporting regulatory agencies onasemnogene abeparvovecs price high earning title worlds expensive medication time commercial later exceeded gene therapies like hemgenix japan negotiated lower price zolgensma public healthcare onasemnogene abeparvovec developed treat spinal muscular atrophy disease linked mutation gene chromosome diagnosed predominantly young children causes progressive loss muscle function frequently death medication administered intravenous united states onasemnogene abeparvovec indicated treatment people less two years age spinal muscular atrophy biallelic mutations survival motor neuron treatment approved united states certain countries use children spinal muscular atrophy age two including presymptomatic stage european union canada indicated treatment people spinal muscular atrophy either clinical diagnosis spinal muscular atrophy type three copies common adverse reactions may include nausea elevated liver serious adverse reactions may include liver problems low transient elevated levels cardiac observed clinical trials clinical importance findings however cardiac toxicity seen studies sma neuromuscular disorder caused mutation gene leads decrease smn protein protein necessary survival motor neurons onasemnogene abeparvovec biologic drug consisting virus capsids contains transgene along synthetic upon administration viral vector delivers transgene affected motor neurons leads increase smn proteincitation needed onasemnogene abeparvovec developed us biotechnology startup avexis acquired novartis based research conducted institut de myologie us food drug administration fda granted onasemnogene abeparvovecxioi various designations including fast track breakthrough therapy priority review orphan drug additionally fda awarded manufacturer rare pediatric disease priority review voucher approved onasemnogene abeparvovec avexis june european commission granted orphan designation however july drug removed committee medicinal products human use chmp accelerated assessment may onasemnogene abeparvovec received us fda approval treatment children two years since treatment reimbursed march gained regulatory approval japan labeling additionally european medicines agency ema recommended conditional marketing authorization march specifically individuals sma type sma type three copies gene conditional approval granted europe may august onasemnogene abeparvovec received regulatory approval brazil brazilian health regulatory agency subsequently approved medical use canada december australia february russia december according health sciences authority register singapore onasemnogene abeparvovec approved april initially approved united states children onasemnogene abeparvovecs approval varies different drug carries list price million per treatment making expensive medication world first full quarter sales million medication japan drug made available public health care system may making expensive drug covered japanese public health care central social insurance medical council responsible approving universal drug fee schedule japan negotiated price approx usd per months leading medications approval us food drug administration fda whistleblower informed novartis certain studies medication subject data novartis fired two avexis executives determined responsible alleged data manipulation informed fda data integrity issue june month drugs delay drew strong condemnation october company admitted informed fda european medicines agency ema seven months toxic effects intravenous formulation observed laboratory due data manipulation issue ema withdrew decision allow accelerated assessment december novartis announced would donate doses onasemnogene abeparvovec per year children outside us global lottery decision claimed novartis based recommendation unnamed received much criticism european european healthcare patient groups see emotionally burdening suboptimal ethically novartis consult families doctors announcing novartis faced criticism donating onasemnogene abeparvovec doses lottery onasemnogene abeparvovec international nonproprietary name united states adopted name httpsenwikipediaorgwikionasemnogeneabeparvovec